- Combination of NOX66 + pioneering form of radiotherapy
- Late-stage prostate cancer patients
- Safety and efficacy study
29 May, Sydney: Noxopharm (ASX:NOX) today announces the involvement of its experimental drug, NOX66, in a clinical study looking at the ability of a pioneering form of radiotherapy to boost survival prospects in men with late-stage prostate cancer.
For further information please download PDF attached:
Download this document
